Methyl cholanate | 25941-29-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Methyl cholanate
• 英文别名: methyl (4R)-4-[(8R,9S,10S,13R,14S,17R)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate
• CAS: 25941-29-1
• 化学式: C₂₅H₄₂O₂
• 分子量: 374.607
• InChiKey: YHTRVWPOAJKWBV-OAFMNPBWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  、 Methyl cholanate 、 乙酰氯 、 胆酸 在 ice 、 水 作用下， 以 甲醇 为溶剂， 反应 2.25h， 以610 g (98%) of methyl cholate (melting point 154° C.) are obtained的产率得到胆酸甲酯
  参考文献：
  名称：

  Process for the preparation of 3.beta.-aminocholanic acid derivatives

  摘要：

  一种制备3.beta.-氨基胆酸衍生物的方法，其化学式为II ##STR1## 其中R（1）、R（2）和R（3）具有所给出的含义，从相应的3.beta.-羟基胆酸酯出发进行。

  公开号：

  US05486626A1

文献信息

• [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF OBETICHOLIC ACID AND INTERMEDIATES USED IN THE PROCESS THEREOF<br/>[FR] PROCÉDÉ AMÉLIORÉ POUR LA PRÉPARATION D'ACIDE OBÉTICHOLIQUE ET INTERMÉDIAIRES UTILISÉS DANS LE PROCÉDÉ
  申请人：SOLARA ACTIVE PHARMA SCIENCES LTD

  公开号：WO2020039449A1

  公开（公告）日：2020-02-27

  The present invention relates to an improved process for the preparation of Obeticholic acid and intermediates used in the process thereof. The invention also relates to a solid form of tertiary butylamine salt of Obeticholic acid and tertiary butylamine salt of Obeticholic acid in the solvate form.

  本发明涉及一种改进的制备Obeticholic酸及其中间体的工艺。本发明还涉及Obeticholic酸的叔丁基胺盐的固体形式，以及Obeticholic酸的叔丁基胺盐的溶剂化形式。
• PURIFICATION PROCESS FOR CHENODEOXYCHOLIC ACID
  申请人：DAEWOONG BIO INC.

  公开号：EP1966228B1

  公开（公告）日：2015-01-21
• DEVELOPMENT AND EVALUATION OF NOVEL CHINESE MATERIA MEDICA PREPARATIONS
  申请人：Song Ching

  公开号：US20120309700A1

  公开（公告）日：2012-12-06

  Nuclear receptor LXR is an important member of 49 nuclear receptors in human bodies and has irreplaceable regulatory effects on cholesterol and fat metabolisms. The regulation of the biological activity of LXR may have therapeutic effects to the conditions such as cardiovascular and cerebrovascular obstructions, non-insulin dependent hyperglycemia, immune function disorders, and central nerve functional degeneration. We have developed a group of novel Chinese materia medica preparations targeting nuclear receptor LXR by using a computer-simulated docking technology and a process for determining biological activities of human cells cultured ex vivo. The group of preparations are featured by simple ingredients, low costs, easy to prepare, etc. No significant adverse effects were found in initial acute toxicology analysis which was carried out using mice.
• Hyaluronic Acid-Based Nanoparticles as Biosensors for Imaging-Guided Surgery and Drug Delivery Vehicles and Methods Associated Therewith
  申请人：WAKE FOREST UNIVERSITY

  公开号：US20170202982A1

  公开（公告）日：2017-07-20

  The present invention relates to intraoperative fluorescent imaging (IFI) used both pre-clinically using in-vivo models, as well as clinically to map sentinel lymph nodes in breast cancer, skin cancer, GI cancer, lung cancer, prostate cancer and several other cancers. IFI can be used to image solid tumors both non-specifically in hepatobiliary and breast cancers as well as in prostate and ovarian cancer. In one embodiment, two-dimensional resolution to 10 μm 2 is possible with optical imaging, significantly higher than other imaging modalities. In one embodiment, the present invention relates to a series of self-assembled nanoparticles using HLA (hyaluronic acid) as both a polymeric backbone as well as targeting ligand. In some embodiments, the present invention relates to the synthesis of HLA conjugates, and the effect of variation of the hydrophobic ligand structure and conjugation level on nanoparticle self-assembly, size, ICG loading efficiency, and ICG fluorescence quenching and reactivation.
• [DE] GALLENSÄUREKONJUGATE UND DAMIT GEBILDETE PARTIKEL<br/>[EN] BILE ACID CONJUGATES AND PARTICLES FORMED THEREWITH<br/>[FR] CONJUGUES D'ACIDE BILIAIRE ET PARTICULES FORMEES A L'AIDE DE CES CONJUGUES
  申请人：WIELAND HEINRICH

  公开号：WO2004037275A1

  公开（公告）日：2004-05-06

  Es wird ein Konjugat beschrieben, die eine Lipid-Struktureinheit, eine Gallensäure- oder Gallensalz-Struktureinheit, und gegebenenfalls eine Linker-Struktureinheit aufweist, wobei die Lipid-Struktureinheit und die Gallensäure- bzw. Gallensalz-Struktureinheit kovalent, gegebenenfalls über die dazwischenliegende Linker-Struktureinheit, verbunden sind. Mit solchen Konjugaten können, je nach Wunsch mit weiteren Bestandteilen, sehr nützliche Partikel, insbesondere Liposomen oder ähnliche vesikuläre Teilchen, aufgebaut werden. Solche Konjugate und Partikel, die die Konjugate umfassen bzw. gebunden enthalten, sind für therapeutische Anwendungen, insbesondere für die Target­und speziell die Leber-spezifische Therapie besonders gut geeignet.